Analysis Forecast

Ulcerative Colitis Therapeutics Analysis, Clinical Trials and Developments

Ulcerative Colitis therapeutics currently exhibits a proliferating pipeline with 50+ therapeutic candidates.

Ulcerative colitis (UC) is a disease that affects colon or large intestine and results in inflammation of the colon and development of ulcers on intestinal linings. The disease is a result of improper functioning of immune system. As a repercussion, white blood cells (WBCs) reach the lining of large intestine, resulting in its inflammation. Signs of the disease usually are cramps in abdominal region, bloody stools, lose or urgent bowel movements, and others. The disease is non-contagious. Moreover, family history is a significant risk factor for the disease.

Download sample copy of this report:

Treatment options for UC include infliximab, tofacitinib, aminosalicylate, corticosteroid, immunosuppressant, and ciclosporin for the reduction of inflammation. Surgery is the ultimate solution for the disease in extreme cases. The diagnosis of the disease is possible through physical examination and lab tests.

Companies that are involved in developing therapeutics for UC have shown positive clinical results in various phases of drug development. For instance, GW Pharmaceuticals plc, announced positive preliminary top-line results of phase IIa trial evaluating GWP42003 extract for treatment of UC in October 2014, which revealed that patients administered with the drug showed positive effects for UC.

Pre-Purchase Inquiry at:

Some of the key players involved in the development of UC therapeutics are Pfizer Inc., Takeda Pharmaceutical Company Limited, Seres Therapeutics Inc., Janssen Biotech Inc., Receptos Inc., EA Pharma Co. Ltd., Celgene Corporation, and InDex Pharmaceuticals AB.